Murali M. Yallapu, PhD

Research Interest: chemotherapy, cancer, miRNA, nanotechnology, drug delivery, biomaterials.

Dr. Murali Yallapu is a tenured Associate Professor of the Immunology and Microbiology Department and Member of South Texas Center of Excellence in Cancer Research (ST-CECR) at the School of Medicine, University of Texas Rio Grande Valley (UTRGV), McAllen, Texas, USA. Dr. Yallapu also Co-ordinator for DIM-STCECR Seminar Series and Program Co-ordinator for CPRIT TREC Award ST-CECR. Dr. Yallapu is a recipient of the “Prof. A. Kameswara Rao's Gold Medal‐1999” and NIH Career Transition Awardee. Dr. Yallapu has received his PhD degree in Polymer Science & Technology and completed postdoctoral training in materials science, drug delivery, nanomedicine, and cancer biology from Cleveland Clinic, University of Nebraska Medical Center, Sanford Research, and Gwangju Institute of Science & Technology. Before Joining the UTRGV, Dr. Yallapu served as Assistant Professor at the Department of Pharmaceutical Sciences, The University of Tennessee Health Science Center. Dr. Yallapu has been serving as Editorial Board Member for various drug delivery, nanotechnology, and cancer related journals. He has been an ad‐hoc reviewer for NIH and various other funding agency study sections. He has published over 175 peer‐reviewed articles and reviews in journals, book chapters, and over 135 conference abstracts. His work was cited over 14815 times, with an H‐index of 59 and an i10‐index of 149. His current research primarily focuses on the development of nanomaterials for improved therapeutic potential of clinical drug(s) and developing new constructs for biomedical applications. Additionally, through cancer immunology institute we will generate safe and effective nanoformulations for cancer immunotherapy.

Editorial Board
Terms of Appointment: August 2022 - July 2024